Chronic Idiopathic Constipation Therapeutics
1. Amitiza patent expiration
Treatment: Method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable exci...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8097653 | SUCAMPO | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(3 years ago) | |
| US8071613 | SUCAMPO | Anti-constipation composition |
Sep, 2020
(5 years ago) | |
| US8114890 | SUCAMPO | Anti-constipation composition |
Sep, 2020
(5 years ago) | |
| US8389542 | SUCAMPO | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(3 years ago) | |
| US5284858 | SUCAMPO | Prostaglandins E and anti ulcers containing same |
Jul, 2014
(11 years ago) | |
| US8088934 | SUCAMPO | Composition and method for stabilizing the same |
May, 2021
(4 years ago) | |
| US7064148 | SUCAMPO | Chloride channel opener |
Aug, 2022
(3 years ago) | |
| US6583174 | SUCAMPO | Composition and method for stabilizing the same |
Oct, 2020
(5 years ago) | |
| US6414016 | SUCAMPO | Anti-constipation composition |
Sep, 2020
(5 years ago) | |
| US7417067 | SUCAMPO | Composition and method for stabilizing the same |
Oct, 2020
(5 years ago) | |
| US8097649 | SUCAMPO | Composition and method for stabilizing the same |
Oct, 2020
(5 years ago) | |
| US6982283 | SUCAMPO | Method for treating drug-induced constipation |
Dec, 2022
(3 years ago) | |
| US7795312 | SUCAMPO | Method for treating abdominal discomfort |
Sep, 2024
(1 year, 5 months ago) | |
| US8748481 | SUCAMPO | Method for treating gastrointestinal disorder |
Sep, 2025
(5 months ago) | |
| US8779187 | SUCAMPO | Soft-gelatin capsule formulation |
Jan, 2027
(10 months from now) | |
| US8026393 | SUCAMPO | Soft-gelatin capsule formulation |
Oct, 2027
(1 year, 8 months from now) | |
| US8338639 | SUCAMPO | Soft-gelatin capsule formulation |
Jan, 2027
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-670) | Apr 19, 2016 |
| M(M-225) | Apr 26, 2021 |
Drugs and Companies using LUBIPROSTONE ingredient
Market Authorisation Date: 29 April, 2008
Dosage: CAPSULE
How can I launch a generic of AMITIZA before it's drug patent expiration?
More Information on Dosage
AMITIZA family patents
2. Linzess patent expiration
Treatment: Method of treating of irritable bowel syndrome with constipation (ibs-c) in pediatric patients 7 years of age and older; Method of treating chronic...
LINZESS's oppositions filed in EPO
Can you believe LINZESS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7304036 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Aug, 2026
(6 months from now) | |
| US7745409 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(2 years ago) | |
| US7704947 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(2 years ago) | |
| US8080526 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(2 years ago) | |
| US7371727 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9708371 | ABBVIE | Treatments for gastrointestinal disorders |
Aug, 2033
(7 years from now) | |
|
US10702576 (Pediatric) | ABBVIE | Stable Formulations Of Linaclotide |
Feb, 2032
(5 years from now) | |
|
US9708371 (Pediatric) | ABBVIE | Treatments For Gastrointestinal Disorders |
Feb, 2034
(7 years from now) | |
| US8110553 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(2 years ago) | |
| US8933030 | ABBVIE | Treatments for gastrointestinal disorders |
Feb, 2031
(4 years from now) | |
| US8748573 | ABBVIE | Formulations comprising linaclotide |
Oct, 2031
(5 years from now) | |
| US10702576 | ABBVIE | Stable formulations of linaclotide |
Aug, 2031
(5 years from now) | |
|
US8748573 (Pediatric) | ABBVIE | Formulations Comprising Linaclotide |
Apr, 2032
(6 years from now) | |
|
US7304036 (Pediatric) | ABBVIE | Methods And Compositions For The Treatment Of Gastrointestinal Disorders |
Feb, 2027
(1 year, 6 days from now) | |
| US8802628 | ABBVIE | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration |
Oct, 2031
(5 years from now) | |
| US10675325 | ABBVIE | Stable formulations of linaclotide |
Aug, 2031
(5 years from now) | |
|
US8933030 (Pediatric) | ABBVIE | Treatments For Gastrointestinal Disorders |
Aug, 2031
(5 years from now) | |
|
US8802628 (Pediatric) | ABBVIE | Stable Solid Formulation Of A Gc-C Receptor Agonist Polypeptide Suitable For Oral Administration |
Apr, 2032
(6 years from now) | |
|
US10675325 (Pediatric) | ABBVIE | Stable Formulations Of Linaclotide |
Feb, 2032
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2017 |
| New Strength(NS) | Jan 25, 2020 |
| New Indication(I-921) | Jun 12, 2026 |
| New Patient Population(NPP) | Nov 04, 2028 |
| Pediatric Exclusivity(PED) | May 04, 2029 |
Drugs and Companies using LINACLOTIDE ingredient
NCE-1 date: 30 August, 2016
Market Authorisation Date: 25 January, 2017
Dosage: CAPSULE
How can I launch a generic of LINZESS before it's drug patent expiration?
More Information on Dosage
LINZESS family patents
3. Trulance patent
expiration
Treatment: Elevation of intracellular cgmp resulting in increased intestinal fluid and accelerated transit; chronic idiopathic constipation; Irritable ...
TRULANCE's oppositions filed in EPO
TRULANCE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7799897 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jun, 2022
(3 years ago) | |
| US7041786 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jan, 2028
(1 year, 11 months from now) | |
| US10011637 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8637451 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Mar, 2022
(3 years ago) | |
| US9919024 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(5 years from now) | |
| US9610321 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(5 years from now) | |
| US12146003 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(8 years from now) | |
| US9925231 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(5 years from now) | |
| US9616097 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Aug, 2032
(6 years from now) | |
| US11142549 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(8 years from now) | |
| US11834521 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(8 years from now) | |
| US11319346 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Mar, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-764) | Jan 24, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jan 19, 2022 |
Drugs and Companies using PLECANATIDE ingredient
NCE-1 date: 19 January, 2021
Market Authorisation Date: 19 January, 2017
Dosage: TABLET
How can I launch a generic of TRULANCE before it's drug patent expiration?
More Information on Dosage
TRULANCE family patents